Cargando…
High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria
Nigeria adopted dolutegravir (DTG) as part of first line (1L) antiretroviral therapy (ART) in 2017. However, there is limited documented experience using DTG in sub-Saharan Africa. Our study assessed DTG acceptability from the patient’s perspective as well as treatment outcomes at 3 high-volume faci...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191360/ https://www.ncbi.nlm.nih.gov/pubmed/37196012 http://dx.doi.org/10.1371/journal.pone.0284767 |
_version_ | 1785043447659364352 |
---|---|
author | Abudiore, Opeyemi Amamilo, Ikechukwu Campbell, Jennifer Eigege, Williams Harwell, Joseph Conroy, James Jiboye, Justus Lufadeju, Folu Amole, Carolyn Wiwa, Owens Anweh, Damien Agbaji, Oche Ochai Akanmu, Alani Sulaimon |
author_facet | Abudiore, Opeyemi Amamilo, Ikechukwu Campbell, Jennifer Eigege, Williams Harwell, Joseph Conroy, James Jiboye, Justus Lufadeju, Folu Amole, Carolyn Wiwa, Owens Anweh, Damien Agbaji, Oche Ochai Akanmu, Alani Sulaimon |
author_sort | Abudiore, Opeyemi |
collection | PubMed |
description | Nigeria adopted dolutegravir (DTG) as part of first line (1L) antiretroviral therapy (ART) in 2017. However, there is limited documented experience using DTG in sub-Saharan Africa. Our study assessed DTG acceptability from the patient’s perspective as well as treatment outcomes at 3 high-volume facilities in Nigeria. This is a mixed method prospective cohort study with 12 months of follow-up between July 2017 and January 2019. Patients who had intolerance or contraindications to non-nucleoside reverse-transcriptase inhibitors were included. Patient acceptability was assessed through one-on-one interviews at 2, 6, and 12 months following DTG initiation. ART-experienced participants were asked about side effects and regimen preference compared to their previous regimen. Viral load (VL) and CD4+ cell count tests were assessed according to the national schedule. Data were analysed in MS Excel and SAS 9.4. A total of 271 participants were enrolled on the study, the median age of participants was 45 years, 62% were female. 229 (206 ART-experienced, 23 ART-naive) of enrolled participants were interviewed at 12 months. 99.5% of ART-experienced study participants preferred DTG to their previous regimen. 32% of particpants reported at least one side effect. “Increase in appetite” was most frequently reported (15%), followed by insomnia (10%) and bad dreams (10%). Average adherence as measured by drug pick-up was 99% and 3% reported a missed dose in the 3 days preceding their interview. Among participants with VL results (n = 199), 99% were virally suppressed (<1000 copies/ml), and 94% had VL <50 copies/ml at 12 months. This study is among the first to document self-reported patient experiences with DTG in sub-Saharan Africa and demonstrated high acceptability of DTG-based regimens among patients. The viral suppression rate was higher than the national average of 82%. Our findings support the recommendation of DTG-based regimen as the preferred 1L ART. |
format | Online Article Text |
id | pubmed-10191360 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-101913602023-05-18 High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria Abudiore, Opeyemi Amamilo, Ikechukwu Campbell, Jennifer Eigege, Williams Harwell, Joseph Conroy, James Jiboye, Justus Lufadeju, Folu Amole, Carolyn Wiwa, Owens Anweh, Damien Agbaji, Oche Ochai Akanmu, Alani Sulaimon PLoS One Research Article Nigeria adopted dolutegravir (DTG) as part of first line (1L) antiretroviral therapy (ART) in 2017. However, there is limited documented experience using DTG in sub-Saharan Africa. Our study assessed DTG acceptability from the patient’s perspective as well as treatment outcomes at 3 high-volume facilities in Nigeria. This is a mixed method prospective cohort study with 12 months of follow-up between July 2017 and January 2019. Patients who had intolerance or contraindications to non-nucleoside reverse-transcriptase inhibitors were included. Patient acceptability was assessed through one-on-one interviews at 2, 6, and 12 months following DTG initiation. ART-experienced participants were asked about side effects and regimen preference compared to their previous regimen. Viral load (VL) and CD4+ cell count tests were assessed according to the national schedule. Data were analysed in MS Excel and SAS 9.4. A total of 271 participants were enrolled on the study, the median age of participants was 45 years, 62% were female. 229 (206 ART-experienced, 23 ART-naive) of enrolled participants were interviewed at 12 months. 99.5% of ART-experienced study participants preferred DTG to their previous regimen. 32% of particpants reported at least one side effect. “Increase in appetite” was most frequently reported (15%), followed by insomnia (10%) and bad dreams (10%). Average adherence as measured by drug pick-up was 99% and 3% reported a missed dose in the 3 days preceding their interview. Among participants with VL results (n = 199), 99% were virally suppressed (<1000 copies/ml), and 94% had VL <50 copies/ml at 12 months. This study is among the first to document self-reported patient experiences with DTG in sub-Saharan Africa and demonstrated high acceptability of DTG-based regimens among patients. The viral suppression rate was higher than the national average of 82%. Our findings support the recommendation of DTG-based regimen as the preferred 1L ART. Public Library of Science 2023-05-17 /pmc/articles/PMC10191360/ /pubmed/37196012 http://dx.doi.org/10.1371/journal.pone.0284767 Text en © 2023 Abudiore et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Article Abudiore, Opeyemi Amamilo, Ikechukwu Campbell, Jennifer Eigege, Williams Harwell, Joseph Conroy, James Jiboye, Justus Lufadeju, Folu Amole, Carolyn Wiwa, Owens Anweh, Damien Agbaji, Oche Ochai Akanmu, Alani Sulaimon High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria |
title | High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria |
title_full | High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria |
title_fullStr | High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria |
title_full_unstemmed | High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria |
title_short | High acceptability and viral suppression rate for first-Line patients on a dolutegravir-based regimen: An early adopter study in Nigeria |
title_sort | high acceptability and viral suppression rate for first-line patients on a dolutegravir-based regimen: an early adopter study in nigeria |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191360/ https://www.ncbi.nlm.nih.gov/pubmed/37196012 http://dx.doi.org/10.1371/journal.pone.0284767 |
work_keys_str_mv | AT abudioreopeyemi highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT amamiloikechukwu highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT campbelljennifer highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT eigegewilliams highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT harwelljoseph highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT conroyjames highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT jiboyejustus highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT lufadejufolu highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT amolecarolyn highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT wiwaowens highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT anwehdamien highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT agbajiocheochai highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria AT akanmualanisulaimon highacceptabilityandviralsuppressionrateforfirstlinepatientsonadolutegravirbasedregimenanearlyadopterstudyinnigeria |